Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications
NPLB noted that including factors, such as diminishing returns and dynamic pricing, helps assess medication value better than traditional CEA.
PharmaExec: The Value of Care - Q&A With Peter Rubin, Executive Director at No Patient Left Behind
Rubin speaks about how drugs aren’t being properly valued.
BioCentury: New cost-effectiveness model aims to better capture value of medicines to society
No Patient Left Behind’s updated methodology accounts for disease severity, loss of market exclusivity and social value
BioCentury: Biotech leaders call on peers to lobby for IRA change
Letter calls nine-year price-setting threshold a threat to entire industry
RealClearHealth: For Two Years, Australia Failed People With Cystic Fibrosis; It Can’t Happen Again
Governments around the world have withheld access to life-changing medications for people with cystic fibrosis (CF) for years in the name of being hawkish on drug pricing.
BioCentury: KOLs call for updated Build Back Better to level playing field
Biopharma CEOs, investors call for same timeline for biologics, small molecules and lower out-of-pocket costs